West Pharmaceutical Services Net Income increased by 5.1% to $138.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 54.6%, from $89.80M to $138.80M. Over 4 years (FY 2021 to FY 2025), Net Income shows a downward trend with a -7.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher values indicate greater profitability and financial health, directly impacting shareholder value.
The final bottom-line profit of the company after all operating expenses, non-operating expenses, and income taxes have...
The most common metric for evaluating company performance against industry competitors.
net_income| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $187.30M | $175.60M | $147.70M | $173.80M | $188.50M | $120.60M | $103.00M | $140.00M | $155.10M | $161.30M | $137.00M | $115.30M | $111.30M | $136.00M | $130.10M | $89.80M | $131.80M | $140.00M | $132.10M | $138.80M |
| QoQ Change | — | -6.2% | -15.9% | +17.7% | +8.5% | -36.0% | -14.6% | +35.9% | +10.8% | +4.0% | -15.1% | -15.8% | -3.5% | +22.2% | -4.3% | -31.0% | +46.8% | +6.2% | -5.6% | +5.1% |
| YoY Change | — | — | — | — | +0.6% | -31.3% | -30.3% | -19.4% | -17.7% | +33.7% | +33.0% | -17.6% | -28.2% | -15.7% | -5.0% | -22.1% | +18.4% | +2.9% | +1.5% | +54.6% |